Tomi Pastinen
Concepts (684)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Genomics | 21 | 2024 | 101 | 5.520 |
Why?
| DNA Methylation | 42 | 2024 | 115 | 5.320 |
Why?
| Polymorphism, Single Nucleotide | 62 | 2022 | 348 | 4.700 |
Why?
| Rare Diseases | 6 | 2024 | 48 | 4.420 |
Why?
| Alleles | 39 | 2024 | 214 | 4.080 |
Why?
| Humans | 177 | 2024 | 6896 | 3.700 |
Why?
| Gene Expression Regulation | 30 | 2021 | 101 | 3.280 |
Why?
| Genome-Wide Association Study | 39 | 2024 | 190 | 3.190 |
Why?
| Gene Expression Profiling | 29 | 2024 | 126 | 3.150 |
Why?
| Genetic Variation | 29 | 2024 | 174 | 3.060 |
Why?
| Genome, Human | 20 | 2024 | 86 | 2.800 |
Why?
| Genetic Predisposition to Disease | 34 | 2024 | 231 | 2.530 |
Why?
| Quantitative Trait Loci | 27 | 2024 | 65 | 2.500 |
Why?
| Sequence Analysis, DNA | 24 | 2024 | 115 | 2.490 |
Why?
| Epigenomics | 14 | 2024 | 27 | 2.190 |
Why?
| Epigenesis, Genetic | 25 | 2024 | 68 | 1.990 |
Why?
| Phenotype | 20 | 2024 | 257 | 1.910 |
Why?
| CpG Islands | 23 | 2022 | 53 | 1.740 |
Why?
| Chromosome Mapping | 15 | 2024 | 35 | 1.670 |
Why?
| Female | 70 | 2024 | 3525 | 1.640 |
Why?
| Male | 68 | 2024 | 3337 | 1.640 |
Why?
| High-Throughput Nucleotide Sequencing | 13 | 2024 | 99 | 1.640 |
Why?
| Privacy | 2 | 2023 | 2 | 1.470 |
Why?
| Information Dissemination | 2 | 2023 | 8 | 1.460 |
Why?
| Regulatory Sequences, Nucleic Acid | 10 | 2019 | 16 | 1.410 |
Why?
| Osteoblasts | 8 | 2015 | 21 | 1.370 |
Why?
| Haplotypes | 16 | 2024 | 91 | 1.370 |
Why?
| Genetic Testing | 5 | 2024 | 87 | 1.300 |
Why?
| Child | 32 | 2024 | 3364 | 1.290 |
Why?
| Polymorphism, Genetic | 13 | 2018 | 90 | 1.170 |
Why?
| Mutation | 17 | 2024 | 212 | 1.150 |
Why?
| T-Lymphocytes | 6 | 2021 | 31 | 1.130 |
Why?
| Adult | 34 | 2024 | 1181 | 1.080 |
Why?
| Chromatin | 8 | 2024 | 22 | 1.020 |
Why?
| Multifactorial Inheritance | 2 | 2024 | 17 | 0.980 |
Why?
| Middle Aged | 32 | 2021 | 608 | 0.970 |
Why?
| Asthma | 12 | 2020 | 157 | 0.960 |
Why?
| Sequence Analysis, RNA | 5 | 2020 | 26 | 0.950 |
Why?
| Health Services Accessibility | 1 | 2024 | 39 | 0.920 |
Why?
| Rural Population | 1 | 2024 | 42 | 0.910 |
Why?
| Neurodevelopmental Disorders | 4 | 2024 | 23 | 0.870 |
Why?
| Insurance Coverage | 1 | 2023 | 21 | 0.860 |
Why?
| Software | 6 | 2024 | 30 | 0.850 |
Why?
| Histones | 3 | 2021 | 16 | 0.840 |
Why?
| Genotype | 29 | 2019 | 410 | 0.830 |
Why?
| Cell Line | 15 | 2023 | 81 | 0.810 |
Why?
| Animals | 24 | 2024 | 729 | 0.810 |
Why?
| Trimethoprim, Sulfamethoxazole Drug Combination | 1 | 2022 | 13 | 0.800 |
Why?
| Respiratory Insufficiency | 1 | 2022 | 13 | 0.800 |
Why?
| Oligonucleotide Array Sequence Analysis | 12 | 2015 | 47 | 0.790 |
Why?
| DNA Mutational Analysis | 8 | 2024 | 42 | 0.770 |
Why?
| Bone Density | 10 | 2015 | 43 | 0.770 |
Why?
| Transcription, Genetic | 10 | 2017 | 44 | 0.760 |
Why?
| Vitamin B 12 | 6 | 2022 | 9 | 0.740 |
Why?
| Arthritis, Rheumatoid | 6 | 2024 | 9 | 0.740 |
Why?
| Gene Expression | 10 | 2020 | 67 | 0.700 |
Why?
| Transcriptome | 7 | 2024 | 59 | 0.690 |
Why?
| Aged | 23 | 2021 | 378 | 0.690 |
Why?
| Intellectual Disability | 3 | 2024 | 35 | 0.680 |
Why?
| Autoimmune Diseases | 7 | 2024 | 13 | 0.660 |
Why?
| Adolescent | 21 | 2024 | 2197 | 0.630 |
Why?
| Enhancer Elements, Genetic | 7 | 2021 | 19 | 0.630 |
Why?
| Genetic Diseases, Inborn | 4 | 2011 | 20 | 0.620 |
Why?
| Heterozygote | 7 | 2024 | 26 | 0.610 |
Why?
| Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 2 | 2018 | 7 | 0.600 |
Why?
| Base Sequence | 12 | 2023 | 81 | 0.600 |
Why?
| Membrane Proteins | 8 | 2024 | 54 | 0.550 |
Why?
| Carrier Proteins | 6 | 2018 | 35 | 0.540 |
Why?
| MicroRNAs | 4 | 2020 | 27 | 0.530 |
Why?
| Genetic Privacy | 1 | 2015 | 2 | 0.520 |
Why?
| Gene Regulatory Networks | 8 | 2019 | 16 | 0.510 |
Why?
| Gene Frequency | 12 | 2018 | 90 | 0.500 |
Why?
| Pedigree | 9 | 2023 | 59 | 0.490 |
Why?
| GTPase-Activating Proteins | 2 | 2024 | 2 | 0.490 |
Why?
| Spermatozoa | 3 | 2020 | 22 | 0.480 |
Why?
| Mice | 12 | 2024 | 348 | 0.480 |
Why?
| Genomic Imprinting | 2 | 2011 | 8 | 0.470 |
Why?
| Child, Preschool | 15 | 2024 | 1569 | 0.470 |
Why?
| Organ Specificity | 7 | 2018 | 23 | 0.460 |
Why?
| Neoplasms | 3 | 2024 | 128 | 0.460 |
Why?
| DNA | 8 | 2015 | 41 | 0.450 |
Why?
| Allelic Imbalance | 6 | 2012 | 7 | 0.450 |
Why?
| RNA, Messenger | 8 | 2017 | 115 | 0.450 |
Why?
| Reproducibility of Results | 5 | 2024 | 199 | 0.420 |
Why?
| Promoter Regions, Genetic | 8 | 2021 | 49 | 0.410 |
Why?
| Medicine | 2 | 2023 | 10 | 0.410 |
Why?
| Algorithms | 4 | 2024 | 105 | 0.410 |
Why?
| Membrane Transport Proteins | 3 | 2024 | 16 | 0.410 |
Why?
| Lymphocytes | 5 | 2015 | 15 | 0.410 |
Why?
| Single-Cell Analysis | 2 | 2024 | 18 | 0.410 |
Why?
| Linkage Disequilibrium | 10 | 2018 | 34 | 0.410 |
Why?
| Herpes Simplex | 2 | 2023 | 10 | 0.410 |
Why?
| Monocytes | 4 | 2016 | 9 | 0.410 |
Why?
| Genetics, Medical | 1 | 2011 | 5 | 0.400 |
Why?
| Fractures, Bone | 5 | 2015 | 34 | 0.400 |
Why?
| Brain Neoplasms | 3 | 2019 | 45 | 0.390 |
Why?
| Breast Neoplasms | 3 | 2016 | 38 | 0.390 |
Why?
| Genetic Loci | 9 | 2024 | 40 | 0.380 |
Why?
| Genome | 5 | 2024 | 32 | 0.370 |
Why?
| Osteoporosis | 5 | 2012 | 25 | 0.370 |
Why?
| Diabetes Mellitus, Type 1 | 4 | 2019 | 115 | 0.370 |
Why?
| Adipose Tissue | 4 | 2019 | 27 | 0.370 |
Why?
| Neutrophils | 3 | 2021 | 11 | 0.370 |
Why?
| Environmental Exposure | 1 | 2011 | 29 | 0.370 |
Why?
| Graft vs Host Disease | 3 | 2019 | 12 | 0.370 |
Why?
| Mutation, Missense | 2 | 2024 | 28 | 0.370 |
Why?
| Biomarkers, Tumor | 4 | 2018 | 65 | 0.360 |
Why?
| Cell Line, Tumor | 6 | 2019 | 99 | 0.360 |
Why?
| Neoplasm Proteins | 5 | 2023 | 31 | 0.360 |
Why?
| Cohort Studies | 5 | 2024 | 289 | 0.360 |
Why?
| Folic Acid | 3 | 2019 | 17 | 0.350 |
Why?
| Fibroblasts | 6 | 2018 | 26 | 0.350 |
Why?
| Probability | 1 | 2009 | 15 | 0.340 |
Why?
| Metabolic Diseases | 2 | 2019 | 11 | 0.340 |
Why?
| Risk Factors | 13 | 2018 | 487 | 0.340 |
Why?
| Infant | 10 | 2024 | 1446 | 0.340 |
Why?
| Hematopoietic Stem Cell Transplantation | 3 | 2019 | 50 | 0.340 |
Why?
| Trans-Activators | 2 | 2021 | 14 | 0.330 |
Why?
| Repressor Proteins | 3 | 2017 | 12 | 0.330 |
Why?
| Models, Statistical | 2 | 2024 | 29 | 0.320 |
Why?
| RNA, Long Noncoding | 3 | 2018 | 14 | 0.320 |
Why?
| Cells, Cultured | 7 | 2018 | 84 | 0.320 |
Why?
| Methylenetetrahydrofolate Reductase (NADPH2) | 3 | 2019 | 6 | 0.320 |
Why?
| Computer Simulation | 3 | 2024 | 31 | 0.310 |
Why?
| Homeodomain Proteins | 3 | 2017 | 20 | 0.310 |
Why?
| Lupus Erythematosus, Systemic | 3 | 2017 | 15 | 0.310 |
Why?
| Molecular Sequence Data | 7 | 2014 | 71 | 0.310 |
Why?
| Computational Biology | 4 | 2018 | 43 | 0.300 |
Why?
| Exome | 3 | 2016 | 36 | 0.300 |
Why?
| Drosophila Proteins | 2 | 2024 | 8 | 0.300 |
Why?
| DNA Primers | 4 | 2000 | 30 | 0.300 |
Why?
| Precision Medicine | 4 | 2020 | 45 | 0.290 |
Why?
| Metabolism, Inborn Errors | 2 | 2018 | 6 | 0.290 |
Why?
| Aged, 80 and over | 9 | 2020 | 151 | 0.280 |
Why?
| Immune System Diseases | 2 | 2016 | 6 | 0.280 |
Why?
| Cell Lineage | 2 | 2018 | 22 | 0.280 |
Why?
| Nerve Tissue Proteins | 2 | 2024 | 26 | 0.280 |
Why?
| Coronary Artery Disease | 2 | 2019 | 10 | 0.280 |
Why?
| Rhinitis, Allergic | 2 | 2017 | 10 | 0.280 |
Why?
| Multigene Family | 2 | 2024 | 8 | 0.280 |
Why?
| Sulfites | 3 | 2024 | 5 | 0.270 |
Why?
| Chromatin Immunoprecipitation | 2 | 2017 | 9 | 0.270 |
Why?
| Expressed Sequence Tags | 1 | 2005 | 1 | 0.270 |
Why?
| Young Adult | 8 | 2021 | 647 | 0.260 |
Why?
| Proto-Oncogene Proteins | 2 | 2024 | 18 | 0.250 |
Why?
| Selection, Genetic | 1 | 2024 | 3 | 0.250 |
Why?
| Histocompatibility Testing | 4 | 2019 | 22 | 0.250 |
Why?
| Genetic Markers | 5 | 2012 | 22 | 0.250 |
Why?
| Penetrance | 1 | 2024 | 8 | 0.240 |
Why?
| HLA-B Antigens | 2 | 2022 | 7 | 0.240 |
Why?
| Aging | 2 | 2024 | 39 | 0.240 |
Why?
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 2 | 2016 | 52 | 0.240 |
Why?
| DNA, Single-Stranded | 1 | 2024 | 1 | 0.240 |
Why?
| Base Pair Mismatch | 1 | 2024 | 1 | 0.240 |
Why?
| Autoimmunity | 1 | 2024 | 4 | 0.240 |
Why?
| DNA Damage | 1 | 2024 | 9 | 0.240 |
Why?
| Finland | 10 | 2015 | 11 | 0.240 |
Why?
| Microcephaly | 1 | 2024 | 5 | 0.240 |
Why?
| Fibroblast Growth Factors | 1 | 2024 | 30 | 0.240 |
Why?
| Antibodies, Viral | 2 | 2022 | 47 | 0.240 |
Why?
| Toll-Like Receptors | 1 | 2024 | 14 | 0.240 |
Why?
| Case-Control Studies | 8 | 2020 | 215 | 0.230 |
Why?
| Eosinophilia | 1 | 2024 | 29 | 0.230 |
Why?
| Multiple Sclerosis | 5 | 2003 | 11 | 0.230 |
Why?
| Tandem Repeat Sequences | 1 | 2024 | 7 | 0.230 |
Why?
| Chromosomes, Human, Pair 17 | 4 | 2024 | 7 | 0.230 |
Why?
| Homocystinuria | 2 | 2022 | 3 | 0.230 |
Why?
| Exons | 4 | 2013 | 34 | 0.230 |
Why?
| Cerebellar Ataxia | 1 | 2023 | 4 | 0.230 |
Why?
| Charcot-Marie-Tooth Disease | 1 | 2023 | 1 | 0.230 |
Why?
| Folic Acid Deficiency | 1 | 2023 | 3 | 0.230 |
Why?
| Neuroaxonal Dystrophies | 1 | 2023 | 2 | 0.230 |
Why?
| Attitude | 1 | 2023 | 10 | 0.220 |
Why?
| Encephalitis, Herpes Simplex | 1 | 2023 | 3 | 0.220 |
Why?
| Herpesvirus 1, Human | 1 | 2023 | 4 | 0.220 |
Why?
| Interferon Type I | 1 | 2023 | 5 | 0.220 |
Why?
| Transcription Factors | 4 | 2018 | 52 | 0.220 |
Why?
| Lactation | 1 | 2023 | 5 | 0.220 |
Why?
| Epilepsy | 1 | 2023 | 14 | 0.220 |
Why?
| Cell Differentiation | 3 | 2018 | 59 | 0.220 |
Why?
| Drug Therapy | 2 | 2013 | 7 | 0.220 |
Why?
| Milk, Human | 1 | 2023 | 23 | 0.220 |
Why?
| Muscular Atrophy, Spinal | 1 | 2023 | 2 | 0.220 |
Why?
| Non-alcoholic Fatty Liver Disease | 1 | 2023 | 20 | 0.220 |
Why?
| Cardiovascular System | 1 | 2022 | 4 | 0.220 |
Why?
| Intracellular Signaling Peptides and Proteins | 4 | 2024 | 21 | 0.220 |
Why?
| Eosinophils | 2 | 2020 | 29 | 0.220 |
Why?
| Urinary Tract | 1 | 2022 | 10 | 0.210 |
Why?
| Influenza, Human | 1 | 2024 | 68 | 0.210 |
Why?
| Polymerase Chain Reaction | 6 | 2001 | 84 | 0.210 |
Why?
| Viral Vaccines | 1 | 2022 | 10 | 0.210 |
Why?
| Primates | 2 | 2024 | 3 | 0.210 |
Why?
| Human Growth Hormone | 1 | 2022 | 15 | 0.210 |
Why?
| Molecular Sequence Annotation | 3 | 2016 | 9 | 0.210 |
Why?
| Growth Disorders | 1 | 2022 | 25 | 0.210 |
Why?
| HLA-B7 Antigen | 1 | 2022 | 2 | 0.200 |
Why?
| HLA-C Antigens | 1 | 2022 | 3 | 0.200 |
Why?
| Gene Expression Regulation, Neoplastic | 6 | 2019 | 59 | 0.200 |
Why?
| Dexamethasone | 3 | 2015 | 29 | 0.200 |
Why?
| Genetic Association Studies | 3 | 2020 | 53 | 0.200 |
Why?
| Databases, Genetic | 4 | 2024 | 30 | 0.200 |
Why?
| Parents | 1 | 2023 | 157 | 0.200 |
Why?
| Nasal Mucosa | 1 | 2021 | 8 | 0.200 |
Why?
| Vascular Endothelial Growth Factor Receptor-2 | 1 | 2021 | 1 | 0.200 |
Why?
| Tetralogy of Fallot | 1 | 2021 | 2 | 0.200 |
Why?
| Bone and Bones | 3 | 2015 | 17 | 0.190 |
Why?
| Basic Helix-Loop-Helix Transcription Factors | 2 | 2015 | 14 | 0.190 |
Why?
| Monomeric GTP-Binding Proteins | 1 | 2021 | 2 | 0.190 |
Why?
| Body Height | 2 | 2011 | 34 | 0.190 |
Why?
| Spike Glycoprotein, Coronavirus | 1 | 2021 | 19 | 0.190 |
Why?
| Egg Proteins | 2 | 2012 | 4 | 0.190 |
Why?
| Dermatitis, Atopic | 1 | 2020 | 7 | 0.190 |
Why?
| Poly A | 1 | 2020 | 1 | 0.190 |
Why?
| Colorectal Neoplasms | 2 | 2018 | 29 | 0.190 |
Why?
| RNA, Ribosomal | 1 | 2020 | 3 | 0.190 |
Why?
| Pregnancy Complications, Infectious | 1 | 2020 | 17 | 0.190 |
Why?
| Markov Chains | 2 | 2018 | 8 | 0.180 |
Why?
| Immune System | 2 | 2017 | 4 | 0.180 |
Why?
| Child Abuse | 1 | 2021 | 46 | 0.180 |
Why?
| Hematopoietic Stem Cells | 2 | 2016 | 22 | 0.180 |
Why?
| Hypersensitivity | 1 | 2020 | 56 | 0.170 |
Why?
| Pregnancy | 4 | 2023 | 216 | 0.170 |
Why?
| CD4-Positive T-Lymphocytes | 3 | 2020 | 11 | 0.170 |
Why?
| Bone Morphogenetic Protein 2 | 2 | 2011 | 4 | 0.170 |
Why?
| Genetic Techniques | 1 | 2019 | 6 | 0.170 |
Why?
| Graft vs Leukemia Effect | 1 | 2019 | 1 | 0.170 |
Why?
| Phospholipid Transfer Proteins | 1 | 2019 | 1 | 0.170 |
Why?
| Minor Histocompatibility Antigens | 1 | 2019 | 12 | 0.170 |
Why?
| Epistasis, Genetic | 2 | 2018 | 4 | 0.170 |
Why?
| Microtubule-Associated Proteins | 2 | 2018 | 5 | 0.170 |
Why?
| Protein Processing, Post-Translational | 2 | 2021 | 6 | 0.170 |
Why?
| Chromosomes, Human, Pair 19 | 2 | 2013 | 6 | 0.170 |
Why?
| Oxidoreductases | 5 | 2022 | 9 | 0.170 |
Why?
| Polycomb Repressive Complex 2 | 1 | 2019 | 7 | 0.170 |
Why?
| Histone Code | 4 | 2021 | 6 | 0.170 |
Why?
| RNA | 2 | 2015 | 14 | 0.160 |
Why?
| Glioblastoma | 1 | 2019 | 17 | 0.160 |
Why?
| Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2018 | 3 | 0.160 |
Why?
| DNA Transposable Elements | 2 | 2017 | 2 | 0.160 |
Why?
| Chromosomes, Human | 1 | 2018 | 3 | 0.160 |
Why?
| Germinal Center | 1 | 2018 | 1 | 0.160 |
Why?
| Codon, Nonsense | 1 | 2018 | 6 | 0.160 |
Why?
| Myocardial Infarction | 1 | 1998 | 5 | 0.160 |
Why?
| Hodgkin Disease | 1 | 2018 | 3 | 0.160 |
Why?
| Hematologic Neoplasms | 1 | 2018 | 1 | 0.160 |
Why?
| Cell Transformation, Neoplastic | 1 | 2018 | 16 | 0.160 |
Why?
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2009 | 71 | 0.160 |
Why?
| Practice Guidelines as Topic | 1 | 2019 | 108 | 0.160 |
Why?
| Cardiovascular Diseases | 1 | 2019 | 48 | 0.160 |
Why?
| Cluster Analysis | 3 | 2020 | 43 | 0.160 |
Why?
| Receptors, CCR5 | 1 | 1998 | 1 | 0.160 |
Why?
| Neoplasm Recurrence, Local | 1 | 2018 | 31 | 0.160 |
Why?
| HLA Antigens | 1 | 2018 | 13 | 0.160 |
Why?
| Genes, Regulator | 2 | 2015 | 4 | 0.160 |
Why?
| PAX7 Transcription Factor | 1 | 2018 | 1 | 0.150 |
Why?
| Peroxiredoxins | 1 | 2018 | 1 | 0.150 |
Why?
| HIV-1 | 1 | 1998 | 26 | 0.150 |
Why?
| Stroke | 1 | 2018 | 22 | 0.150 |
Why?
| Transcriptional Elongation Factors | 1 | 2017 | 1 | 0.150 |
Why?
| Chromosomes, Human, Pair 5 | 1 | 2017 | 4 | 0.150 |
Why?
| Multiple Myeloma | 1 | 2017 | 4 | 0.150 |
Why?
| Hindlimb | 1 | 2017 | 1 | 0.150 |
Why?
| Paired Box Transcription Factors | 1 | 2017 | 1 | 0.150 |
Why?
| Organogenesis | 1 | 2017 | 2 | 0.150 |
Why?
| HEK293 Cells | 3 | 2024 | 32 | 0.150 |
Why?
| HIV Infections | 1 | 1998 | 50 | 0.150 |
Why?
| Models, Genetic | 4 | 2018 | 33 | 0.150 |
Why?
| Scleroderma, Systemic | 1 | 2017 | 1 | 0.150 |
Why?
| Rheumatic Diseases | 1 | 2017 | 2 | 0.150 |
Why?
| Conserved Sequence | 1 | 2017 | 5 | 0.150 |
Why?
| Supervised Machine Learning | 1 | 2017 | 2 | 0.150 |
Why?
| Gene Ontology | 3 | 2021 | 6 | 0.140 |
Why?
| Immediate-Early Proteins | 1 | 2017 | 2 | 0.140 |
Why?
| RNA, Untranslated | 1 | 2017 | 7 | 0.140 |
Why?
| Chromosomes, Human, Pair 4 | 1 | 2016 | 2 | 0.140 |
Why?
| Human Genome Project | 1 | 2016 | 3 | 0.140 |
Why?
| Cytosine | 3 | 2024 | 5 | 0.140 |
Why?
| Stem Cells | 1 | 2017 | 29 | 0.140 |
Why?
| Dietary Supplements | 2 | 2015 | 25 | 0.140 |
Why?
| Genes, BRCA2 | 1 | 2016 | 5 | 0.140 |
Why?
| Genes, BRCA1 | 1 | 2016 | 6 | 0.140 |
Why?
| Obesity | 4 | 2024 | 125 | 0.140 |
Why?
| Drosophila melanogaster | 3 | 2005 | 5 | 0.140 |
Why?
| Transcobalamins | 1 | 2016 | 2 | 0.140 |
Why?
| Cytoplasm | 1 | 2016 | 7 | 0.140 |
Why?
| Thyroid Gland | 1 | 2016 | 3 | 0.140 |
Why?
| Congenital Hypothyroidism | 1 | 2016 | 4 | 0.140 |
Why?
| Cell Separation | 1 | 2016 | 7 | 0.140 |
Why?
| Genetic Heterogeneity | 1 | 2016 | 5 | 0.140 |
Why?
| Receptor, Melatonin, MT1 | 1 | 2016 | 1 | 0.140 |
Why?
| Azacitidine | 2 | 2018 | 3 | 0.130 |
Why?
| Mice, Inbred C57BL | 4 | 2024 | 92 | 0.130 |
Why?
| Europe | 3 | 2016 | 37 | 0.130 |
Why?
| Gene-Environment Interaction | 1 | 2015 | 13 | 0.130 |
Why?
| Neuromyelitis Optica | 1 | 2015 | 1 | 0.130 |
Why?
| Histocompatibility Antigens | 1 | 2015 | 2 | 0.130 |
Why?
| Diabetes, Gestational | 1 | 2015 | 4 | 0.130 |
Why?
| Mitochondrial Proteins | 4 | 2018 | 7 | 0.130 |
Why?
| Dendritic Cells | 1 | 2015 | 6 | 0.130 |
Why?
| Host-Pathogen Interactions | 1 | 2015 | 8 | 0.130 |
Why?
| Insulin-Like Growth Factor I | 2 | 2022 | 8 | 0.130 |
Why?
| Data Anonymization | 1 | 2015 | 2 | 0.130 |
Why?
| Oligodendroglioma | 1 | 2015 | 2 | 0.130 |
Why?
| Osteogenesis | 1 | 2015 | 6 | 0.130 |
Why?
| Calcification, Physiologic | 1 | 2015 | 3 | 0.130 |
Why?
| Prednisone | 1 | 2015 | 12 | 0.130 |
Why?
| Bacterial Infections | 1 | 2015 | 27 | 0.130 |
Why?
| Cholesterol, HDL | 1 | 2015 | 10 | 0.130 |
Why?
| Triglycerides | 1 | 2015 | 22 | 0.130 |
Why?
| Tumor Necrosis Factor-alpha | 1 | 2015 | 15 | 0.130 |
Why?
| Antirheumatic Agents | 1 | 2015 | 12 | 0.130 |
Why?
| HeLa Cells | 2 | 2018 | 17 | 0.130 |
Why?
| Colonic Neoplasms | 1 | 2015 | 7 | 0.130 |
Why?
| Femur | 3 | 2009 | 10 | 0.130 |
Why?
| Methionine | 2 | 2019 | 6 | 0.120 |
Why?
| Immunoglobulin E | 1 | 2015 | 22 | 0.120 |
Why?
| Adrenal Cortex Hormones | 1 | 2015 | 37 | 0.120 |
Why?
| DNA Footprinting | 1 | 2014 | 1 | 0.120 |
Why?
| Transcriptional Activation | 2 | 2015 | 9 | 0.120 |
Why?
| Amino Acid Sequence | 1 | 2014 | 32 | 0.120 |
Why?
| Genotyping Techniques | 1 | 2014 | 22 | 0.120 |
Why?
| 3' Untranslated Regions | 3 | 2013 | 10 | 0.120 |
Why?
| Neoplasms, Germ Cell and Embryonal | 1 | 2013 | 1 | 0.120 |
Why?
| Leukocytes, Mononuclear | 2 | 2024 | 16 | 0.120 |
Why?
| Disease | 2 | 2012 | 7 | 0.120 |
Why?
| X Chromosome Inactivation | 1 | 2013 | 3 | 0.120 |
Why?
| Chromosomes, Human, X | 1 | 2013 | 6 | 0.120 |
Why?
| Protein Isoforms | 2 | 2013 | 16 | 0.110 |
Why?
| Chromosome Aberrations | 1 | 2013 | 12 | 0.110 |
Why?
| Trypanosoma brucei brucei | 1 | 2013 | 1 | 0.110 |
Why?
| RNA, Protozoan | 1 | 2013 | 1 | 0.110 |
Why?
| Regulatory Sequences, Ribonucleic Acid | 1 | 2013 | 1 | 0.110 |
Why?
| RNA Stability | 1 | 2013 | 4 | 0.110 |
Why?
| DNA Copy Number Variations | 2 | 2024 | 37 | 0.110 |
Why?
| Core Binding Factor Alpha 2 Subunit | 1 | 2013 | 1 | 0.110 |
Why?
| Proto-Oncogene Proteins c-ets | 1 | 2013 | 1 | 0.110 |
Why?
| Transcription Initiation Site | 1 | 2013 | 2 | 0.110 |
Why?
| Menarche | 1 | 2013 | 4 | 0.110 |
Why?
| Hypertension | 1 | 2014 | 66 | 0.110 |
Why?
| BRCA1 Protein | 1 | 2013 | 8 | 0.110 |
Why?
| Microfilament Proteins | 2 | 2010 | 12 | 0.110 |
Why?
| Protein Biosynthesis | 1 | 2013 | 2 | 0.110 |
Why?
| Sex Characteristics | 1 | 2012 | 12 | 0.110 |
Why?
| Introns | 2 | 2010 | 7 | 0.110 |
Why?
| Gene Expression Regulation, Developmental | 3 | 2018 | 51 | 0.110 |
Why?
| Genetic Complementation Test | 2 | 2010 | 4 | 0.100 |
Why?
| Lectins | 1 | 2012 | 2 | 0.100 |
Why?
| Adipokines | 1 | 2012 | 2 | 0.100 |
Why?
| Toll-Like Receptor 3 | 2 | 2023 | 6 | 0.100 |
Why?
| Ovarian Neoplasms | 1 | 2013 | 136 | 0.100 |
Why?
| Cyclic Nucleotide Phosphodiesterases, Type 4 | 1 | 2011 | 1 | 0.100 |
Why?
| Adrenergic beta-Agonists | 1 | 2011 | 5 | 0.100 |
Why?
| Bronchodilator Agents | 1 | 2011 | 11 | 0.100 |
Why?
| Gastrointestinal Neoplasms | 1 | 2010 | 7 | 0.090 |
Why?
| Germ-Line Mutation | 1 | 2010 | 10 | 0.090 |
Why?
| Dinoprostone | 1 | 2011 | 8 | 0.090 |
Why?
| RNA Splicing | 1 | 2010 | 14 | 0.090 |
Why?
| Apolipoproteins B | 1 | 2010 | 1 | 0.090 |
Why?
| Metabolic Networks and Pathways | 1 | 2010 | 10 | 0.090 |
Why?
| Cholesterol, LDL | 1 | 2010 | 7 | 0.090 |
Why?
| DNA Helicases | 2 | 2023 | 5 | 0.090 |
Why?
| Infant, Newborn | 3 | 2023 | 816 | 0.090 |
Why?
| Zebrafish | 2 | 2022 | 10 | 0.090 |
Why?
| Tissue Distribution | 1 | 2010 | 11 | 0.090 |
Why?
| Cell Proliferation | 3 | 2019 | 58 | 0.090 |
Why?
| Genetic Linkage | 2 | 2002 | 12 | 0.090 |
Why?
| Prognosis | 3 | 2017 | 211 | 0.090 |
Why?
| Adiponectin | 1 | 2009 | 3 | 0.090 |
Why?
| Contractile Proteins | 1 | 2009 | 2 | 0.090 |
Why?
| Cell Culture Techniques | 1 | 2010 | 8 | 0.090 |
Why?
| DNA, Complementary | 2 | 2009 | 9 | 0.090 |
Why?
| Interleukin-2 Receptor alpha Subunit | 1 | 2009 | 2 | 0.090 |
Why?
| Chromatin Assembly and Disassembly | 1 | 2009 | 3 | 0.090 |
Why?
| DNA-Binding Proteins | 2 | 2020 | 39 | 0.090 |
Why?
| Lumbar Vertebrae | 4 | 2012 | 12 | 0.090 |
Why?
| Nevus | 1 | 2009 | 1 | 0.090 |
Why?
| Principal Component Analysis | 1 | 2009 | 14 | 0.090 |
Why?
| Precancerous Conditions | 1 | 2009 | 6 | 0.090 |
Why?
| Chromosomes, Human, Pair 9 | 1 | 2009 | 5 | 0.090 |
Why?
| Chromosomes, Human, Pair 22 | 1 | 2009 | 5 | 0.090 |
Why?
| Predictive Value of Tests | 2 | 2020 | 99 | 0.090 |
Why?
| Skin Neoplasms | 1 | 2009 | 11 | 0.080 |
Why?
| CRISPR-Cas Systems | 2 | 2019 | 13 | 0.080 |
Why?
| Molecular Chaperones | 1 | 2009 | 7 | 0.080 |
Why?
| Transplantation, Homologous | 2 | 2019 | 19 | 0.080 |
Why?
| Nuclear Proteins | 2 | 2020 | 52 | 0.080 |
Why?
| Tissue Donors | 2 | 2019 | 30 | 0.080 |
Why?
| Siblings | 2 | 2019 | 7 | 0.080 |
Why?
| Alternative Splicing | 2 | 2020 | 18 | 0.080 |
Why?
| Intercellular Signaling Peptides and Proteins | 2 | 2023 | 11 | 0.080 |
Why?
| Templates, Genetic | 2 | 2000 | 2 | 0.080 |
Why?
| Age Factors | 1 | 2009 | 210 | 0.080 |
Why?
| STAT4 Transcription Factor | 1 | 2008 | 3 | 0.080 |
Why?
| Antibodies, Antinuclear | 1 | 2008 | 3 | 0.080 |
Why?
| Interferon Regulatory Factors | 1 | 2008 | 4 | 0.080 |
Why?
| Osteoprotegerin | 1 | 2008 | 1 | 0.080 |
Why?
| LDL-Receptor Related Proteins | 1 | 2008 | 2 | 0.080 |
Why?
| Leptin | 1 | 2008 | 4 | 0.080 |
Why?
| Circadian Rhythm | 1 | 2008 | 7 | 0.080 |
Why?
| Bone Morphogenetic Proteins | 1 | 2008 | 8 | 0.080 |
Why?
| Transforming Growth Factor beta | 1 | 2008 | 13 | 0.080 |
Why?
| Homozygote | 4 | 2010 | 20 | 0.080 |
Why?
| Glucocorticoids | 1 | 2008 | 32 | 0.080 |
Why?
| Protein Binding | 2 | 2018 | 31 | 0.080 |
Why?
| Receptors, Calcitriol | 1 | 2007 | 9 | 0.070 |
Why?
| Signal Transduction | 1 | 2008 | 132 | 0.070 |
Why?
| Receptors, Chemokine | 1 | 2006 | 1 | 0.070 |
Why?
| Xenograft Model Antitumor Assays | 2 | 2019 | 15 | 0.070 |
Why?
| Biomarkers | 2 | 2024 | 136 | 0.070 |
Why?
| Twins, Monozygotic | 2 | 2016 | 6 | 0.070 |
Why?
| Ribosomal Proteins | 2 | 2018 | 4 | 0.070 |
Why?
| Primary Cell Culture | 2 | 2017 | 5 | 0.070 |
Why?
| Animal Structures | 1 | 2005 | 1 | 0.070 |
Why?
| Models, Biological | 1 | 2006 | 65 | 0.060 |
Why?
| Family Health | 3 | 2018 | 14 | 0.060 |
Why?
| Risk | 2 | 2016 | 41 | 0.060 |
Why?
| Genomic Instability | 2 | 2018 | 2 | 0.060 |
Why?
| Coronary Disease | 2 | 2009 | 5 | 0.060 |
Why?
| Glycoproteins | 2 | 2017 | 9 | 0.060 |
Why?
| Evolution, Molecular | 1 | 2024 | 6 | 0.060 |
Why?
| Retrospective Studies | 2 | 2021 | 1296 | 0.060 |
Why?
| Gene Duplication | 1 | 2024 | 11 | 0.060 |
Why?
| Enteritis | 1 | 2024 | 4 | 0.060 |
Why?
| Eosinophilic Esophagitis | 1 | 2024 | 6 | 0.060 |
Why?
| Nystagmus, Pathologic | 1 | 2024 | 1 | 0.060 |
Why?
| Spastic Paraplegia, Hereditary | 1 | 2024 | 2 | 0.060 |
Why?
| Gastritis | 1 | 2024 | 12 | 0.060 |
Why?
| Deamination | 1 | 2024 | 1 | 0.060 |
Why?
| Cytidine Deaminase | 1 | 2024 | 2 | 0.060 |
Why?
| DNA Replication | 1 | 2024 | 3 | 0.060 |
Why?
| Genome, Mitochondrial | 1 | 2024 | 2 | 0.060 |
Why?
| DNA Mismatch Repair | 1 | 2024 | 4 | 0.060 |
Why?
| Likelihood Functions | 1 | 2024 | 6 | 0.060 |
Why?
| Toll-Like Receptor 7 | 1 | 2024 | 2 | 0.060 |
Why?
| Colitis, Ulcerative | 1 | 2024 | 13 | 0.060 |
Why?
| Crohn Disease | 1 | 2024 | 25 | 0.060 |
Why?
| Multivariate Analysis | 1 | 2024 | 71 | 0.060 |
Why?
| Individuality | 1 | 2024 | 3 | 0.060 |
Why?
| Dosage Compensation, Genetic | 1 | 2004 | 1 | 0.060 |
Why?
| Genes, Insect | 1 | 2004 | 1 | 0.060 |
Why?
| Animals, Genetically Modified | 1 | 2024 | 5 | 0.060 |
Why?
| Drosophila | 1 | 2024 | 7 | 0.060 |
Why?
| Protein Tyrosine Phosphatases | 1 | 2024 | 6 | 0.060 |
Why?
| Quebec | 2 | 2018 | 4 | 0.060 |
Why?
| Extracellular Matrix Proteins | 2 | 2015 | 13 | 0.060 |
Why?
| Developmental Disabilities | 1 | 2024 | 43 | 0.060 |
Why?
| Canada | 2 | 2016 | 31 | 0.060 |
Why?
| Cations | 1 | 2023 | 2 | 0.060 |
Why?
| Sodium-Potassium-Exchanging ATPase | 1 | 2023 | 2 | 0.060 |
Why?
| Muscle Spasticity | 1 | 2023 | 3 | 0.060 |
Why?
| Dichlorodiphenyl Dichloroethylene | 1 | 2023 | 1 | 0.060 |
Why?
| DEAD-box RNA Helicases | 1 | 2023 | 4 | 0.060 |
Why?
| Leucovorin | 1 | 2023 | 2 | 0.060 |
Why?
| Mammals | 1 | 2023 | 4 | 0.060 |
Why?
| Folate Receptor 1 | 1 | 2023 | 2 | 0.060 |
Why?
| Syndrome | 1 | 2023 | 34 | 0.060 |
Why?
| Immunoglobulins | 1 | 2023 | 6 | 0.060 |
Why?
| Chromosomes, Human, Pair 11 | 2 | 2016 | 3 | 0.060 |
Why?
| Intercellular Adhesion Molecule-1 | 1 | 2003 | 3 | 0.060 |
Why?
| Survival of Motor Neuron 1 Protein | 1 | 2023 | 2 | 0.050 |
Why?
| Survival of Motor Neuron 2 Protein | 1 | 2023 | 2 | 0.050 |
Why?
| Sequence Analysis | 1 | 2023 | 3 | 0.050 |
Why?
| Cytokines | 1 | 2023 | 48 | 0.050 |
Why?
| Homocysteine | 1 | 2003 | 1 | 0.050 |
Why?
| Research Design | 1 | 2023 | 63 | 0.050 |
Why?
| Gene Dosage | 1 | 2023 | 13 | 0.050 |
Why?
| Morpholinos | 1 | 2022 | 2 | 0.050 |
Why?
| Central Nervous System | 1 | 2022 | 9 | 0.050 |
Why?
| Linear Models | 2 | 2013 | 56 | 0.050 |
Why?
| Odds Ratio | 2 | 2016 | 51 | 0.050 |
Why?
| Vaccines, Synthetic | 1 | 2022 | 9 | 0.050 |
Why?
| Diet | 1 | 2003 | 52 | 0.050 |
Why?
| Phosphatidylinositol 3-Kinases | 1 | 2022 | 8 | 0.050 |
Why?
| Recombinant Proteins | 1 | 2022 | 48 | 0.050 |
Why?
| Vitamins | 1 | 2022 | 11 | 0.050 |
Why?
| Microsatellite Repeats | 2 | 2002 | 7 | 0.050 |
Why?
| Causality | 1 | 2022 | 10 | 0.050 |
Why?
| Vaccination | 1 | 2022 | 71 | 0.050 |
Why?
| Histocompatibility Antigens Class II | 1 | 2002 | 6 | 0.050 |
Why?
| Bayes Theorem | 1 | 2022 | 30 | 0.050 |
Why?
| Immunity, Cellular | 1 | 2021 | 18 | 0.050 |
Why?
| Immunity, Innate | 1 | 2021 | 16 | 0.050 |
Why?
| Laboratories | 1 | 2021 | 14 | 0.050 |
Why?
| Sensitivity and Specificity | 2 | 2016 | 150 | 0.050 |
Why?
| Vaccine Potency | 1 | 2021 | 7 | 0.050 |
Why?
| Y Chromosome | 1 | 2001 | 1 | 0.050 |
Why?
| Amygdala | 1 | 2021 | 3 | 0.050 |
Why?
| HLA-DQ Antigens | 2 | 2002 | 4 | 0.050 |
Why?
| Diabetes Mellitus, Type 2 | 2 | 2013 | 39 | 0.050 |
Why?
| Immunoglobulin G | 1 | 2021 | 34 | 0.050 |
Why?
| Genes, Reporter | 2 | 2012 | 13 | 0.050 |
Why?
| Complement C6 | 1 | 2020 | 4 | 0.050 |
Why?
| Complement C7 | 1 | 2020 | 4 | 0.050 |
Why?
| RNA Nucleotidyltransferases | 1 | 2020 | 4 | 0.050 |
Why?
| TNF Receptor-Associated Factor 3 | 1 | 2020 | 4 | 0.050 |
Why?
| Interferon Regulatory Factor-3 | 1 | 2020 | 4 | 0.050 |
Why?
| Perforin | 1 | 2020 | 4 | 0.050 |
Why?
| Scavenger Receptors, Class A | 1 | 2020 | 5 | 0.050 |
Why?
| GRB2 Adaptor Protein | 1 | 2020 | 5 | 0.050 |
Why?
| STAT1 Transcription Factor | 1 | 2020 | 6 | 0.050 |
Why?
| Germ Cells | 1 | 2020 | 5 | 0.050 |
Why?
| Databases, Factual | 1 | 2021 | 108 | 0.050 |
Why?
| Fathers | 1 | 2020 | 7 | 0.050 |
Why?
| Gene Library | 1 | 2020 | 5 | 0.050 |
Why?
| Antibodies, Neutralizing | 1 | 2021 | 31 | 0.050 |
Why?
| Machine Learning | 1 | 2020 | 17 | 0.050 |
Why?
| Fertility | 1 | 2020 | 18 | 0.050 |
Why?
| Severity of Illness Index | 1 | 2021 | 149 | 0.050 |
Why?
| Cross-Sectional Studies | 2 | 2001 | 336 | 0.050 |
Why?
| Bacteriophage T7 | 1 | 2000 | 1 | 0.050 |
Why?
| DNA-Directed RNA Polymerases | 1 | 2000 | 2 | 0.050 |
Why?
| Mutagenesis, Site-Directed | 1 | 2000 | 19 | 0.050 |
Why?
| Low Density Lipoprotein Receptor-Related Protein-5 | 2 | 2012 | 5 | 0.050 |
Why?
| Viral Proteins | 1 | 2000 | 8 | 0.050 |
Why?
| Pilot Projects | 1 | 2020 | 120 | 0.050 |
Why?
| Femur Neck | 2 | 2012 | 6 | 0.040 |
Why?
| Adipocytes | 1 | 2019 | 3 | 0.040 |
Why?
| Body Fat Distribution | 1 | 2019 | 4 | 0.040 |
Why?
| Histocompatibility | 1 | 2019 | 2 | 0.040 |
Why?
| Regulatory Elements, Transcriptional | 1 | 2019 | 3 | 0.040 |
Why?
| Insulin | 1 | 2019 | 50 | 0.040 |
Why?
| Regression Analysis | 1 | 2019 | 52 | 0.040 |
Why?
| Disease Progression | 1 | 2019 | 111 | 0.040 |
Why?
| Bioethical Issues | 1 | 2019 | 3 | 0.040 |
Why?
| Incidental Findings | 1 | 2019 | 8 | 0.040 |
Why?
| Blood Glucose | 1 | 2019 | 61 | 0.040 |
Why?
| Lysine | 1 | 2019 | 3 | 0.040 |
Why?
| Neurogenesis | 1 | 2019 | 4 | 0.040 |
Why?
| Mice, Inbred NOD | 1 | 2019 | 7 | 0.040 |
Why?
| Mice, SCID | 1 | 2019 | 13 | 0.040 |
Why?
| Lipids | 1 | 2019 | 8 | 0.040 |
Why?
| Carcinogenesis | 1 | 2019 | 9 | 0.040 |
Why?
| Endothelial Cells | 1 | 2019 | 25 | 0.040 |
Why?
| Blood Cells | 1 | 2018 | 2 | 0.040 |
Why?
| Nucleic Acid Conformation | 1 | 2018 | 1 | 0.040 |
Why?
| Caco-2 Cells | 1 | 2018 | 1 | 0.040 |
Why?
| HT29 Cells | 1 | 2018 | 1 | 0.040 |
Why?
| MCF-7 Cells | 1 | 2018 | 4 | 0.040 |
Why?
| Hep G2 Cells | 1 | 2018 | 6 | 0.040 |
Why?
| K562 Cells | 1 | 2018 | 3 | 0.040 |
Why?
| Serpin E2 | 1 | 2018 | 1 | 0.040 |
Why?
| Neuropilin-2 | 1 | 2018 | 2 | 0.040 |
Why?
| Immunity | 1 | 2018 | 1 | 0.040 |
Why?
| Binding Sites | 1 | 2018 | 26 | 0.040 |
Why?
| Receptors, LDL | 1 | 1998 | 1 | 0.040 |
Why?
| Plasminogen Inactivators | 1 | 1998 | 1 | 0.040 |
Why?
| Platelet Glycoprotein GPIIb-IIIa Complex | 1 | 1998 | 1 | 0.040 |
Why?
| DNA, Neoplasm | 1 | 2018 | 7 | 0.040 |
Why?
| Tumor Cells, Cultured | 1 | 2018 | 25 | 0.040 |
Why?
| NF-kappa B | 1 | 2018 | 14 | 0.040 |
Why?
| Collectins | 1 | 1998 | 1 | 0.040 |
Why?
| HLA-DP beta-Chains | 1 | 2018 | 1 | 0.040 |
Why?
| HLA-A Antigens | 1 | 2018 | 2 | 0.040 |
Why?
| DNA, Viral | 1 | 1998 | 13 | 0.040 |
Why?
| INDEL Mutation | 1 | 2018 | 1 | 0.040 |
Why?
| Genes, Switch | 1 | 2018 | 1 | 0.040 |
Why?
| Myelin Basic Protein | 1 | 1998 | 2 | 0.040 |
Why?
| Enzyme Inhibitors | 1 | 2018 | 21 | 0.040 |
Why?
| Mice, Knockout | 1 | 2018 | 59 | 0.040 |
Why?
| Interferon-gamma | 1 | 1997 | 5 | 0.040 |
Why?
| Diploidy | 1 | 2017 | 1 | 0.040 |
Why?
| Physical Chromosome Mapping | 1 | 2017 | 1 | 0.040 |
Why?
| Transcription Elongation, Genetic | 1 | 2017 | 1 | 0.040 |
Why?
| Unfolded Protein Response | 1 | 2017 | 3 | 0.040 |
Why?
| Forelimb | 1 | 2017 | 1 | 0.040 |
Why?
| Chondrogenesis | 1 | 2017 | 1 | 0.040 |
Why?
| SOX9 Transcription Factor | 1 | 2017 | 1 | 0.040 |
Why?
| Host Cell Factor C1 | 1 | 2017 | 2 | 0.040 |
Why?
| Embryo, Mammalian | 1 | 2017 | 11 | 0.040 |
Why?
| Branchial Region | 1 | 2017 | 7 | 0.040 |
Why?
| DNA-Directed DNA Polymerase | 1 | 1997 | 1 | 0.040 |
Why?
| Nucleic Acid Hybridization | 1 | 1997 | 1 | 0.040 |
Why?
| Craniofacial Abnormalities | 1 | 2017 | 10 | 0.040 |
Why?
| Oligonucleotide Probes | 1 | 1997 | 4 | 0.040 |
Why?
| Antigens, CD1 | 1 | 2017 | 1 | 0.040 |
Why?
| Hepatocyte Nuclear Factor 4 | 1 | 2017 | 3 | 0.040 |
Why?
| Chromosomal Position Effects | 1 | 2017 | 3 | 0.040 |
Why?
| PTEN Phosphohydrolase | 1 | 2017 | 6 | 0.040 |
Why?
| Genes | 2 | 2012 | 10 | 0.040 |
Why?
| Species Specificity | 1 | 2017 | 10 | 0.040 |
Why?
| Fetal Blood | 1 | 2016 | 5 | 0.040 |
Why?
| Sex Factors | 1 | 2017 | 68 | 0.040 |
Why?
| Internet | 1 | 2016 | 17 | 0.040 |
Why?
| HLA-DR2 Antigen | 1 | 1996 | 1 | 0.040 |
Why?
| Gene Amplification | 1 | 1996 | 4 | 0.040 |
Why?
| HLA-DQ alpha-Chains | 1 | 1996 | 3 | 0.040 |
Why?
| Fluorescence | 1 | 1996 | 8 | 0.040 |
Why?
| Risk Assessment | 1 | 2016 | 137 | 0.030 |
Why?
| Twins, Dizygotic | 1 | 2015 | 3 | 0.030 |
Why?
| Comorbidity | 1 | 2016 | 56 | 0.030 |
Why?
| Blood | 1 | 2015 | 10 | 0.030 |
Why?
| Smoking | 1 | 2015 | 22 | 0.030 |
Why?
| Aquaporin 4 | 1 | 2015 | 2 | 0.030 |
Why?
| Time Factors | 1 | 2016 | 250 | 0.030 |
Why?
| Lung | 2 | 2006 | 65 | 0.030 |
Why?
| 5-Methylcytosine | 1 | 2015 | 1 | 0.030 |
Why?
| snRNP Core Proteins | 1 | 2015 | 2 | 0.030 |
Why?
| Mycobacterium tuberculosis | 1 | 2015 | 4 | 0.030 |
Why?
| Tuberculosis | 1 | 2015 | 4 | 0.030 |
Why?
| Wnt Proteins | 1 | 2015 | 11 | 0.030 |
Why?
| Bone Development | 1 | 2015 | 4 | 0.030 |
Why?
| Bone Diseases, Developmental | 1 | 2015 | 3 | 0.030 |
Why?
| Down-Regulation | 1 | 2015 | 15 | 0.030 |
Why?
| Tubulin | 1 | 2015 | 6 | 0.030 |
Why?
| Disease Models, Animal | 1 | 2015 | 71 | 0.030 |
Why?
| Administration, Oral | 1 | 2015 | 58 | 0.030 |
Why?
| Inflammation Mediators | 1 | 2015 | 8 | 0.030 |
Why?
| Genetics, Population | 2 | 2005 | 11 | 0.030 |
Why?
| Open Reading Frames | 1 | 2014 | 3 | 0.030 |
Why?
| Thiamine | 1 | 2014 | 2 | 0.030 |
Why?
| Retinoblastoma-Like Protein p130 | 1 | 2013 | 1 | 0.030 |
Why?
| Gene Fusion | 1 | 2013 | 2 | 0.030 |
Why?
| Genes, X-Linked | 1 | 2013 | 3 | 0.030 |
Why?
| Blood Pressure | 1 | 2014 | 67 | 0.030 |
Why?
| Trypanosoma | 1 | 2013 | 1 | 0.030 |
Why?
| Protozoan Proteins | 1 | 2013 | 1 | 0.030 |
Why?
| Regulon | 1 | 2013 | 1 | 0.030 |
Why?
| ELAV Proteins | 1 | 2013 | 1 | 0.030 |
Why?
| Disease-Free Survival | 1 | 2013 | 45 | 0.030 |
Why?
| Nucleotide Motifs | 1 | 2013 | 3 | 0.030 |
Why?
| Sweden | 2 | 2007 | 28 | 0.030 |
Why?
| Nuclear Receptor Subfamily 1, Group F, Member 1 | 1 | 2013 | 2 | 0.030 |
Why?
| BRCA2 Protein | 1 | 2013 | 8 | 0.030 |
Why?
| Recurrence | 1 | 2013 | 110 | 0.030 |
Why?
| Antineoplastic Agents | 1 | 2013 | 55 | 0.030 |
Why?
| Membrane Glycoproteins | 1 | 2013 | 14 | 0.030 |
Why?
| Polyribosomes | 1 | 2013 | 2 | 0.030 |
Why?
| Meta-Analysis as Topic | 1 | 2012 | 14 | 0.030 |
Why?
| Luciferases | 1 | 2012 | 6 | 0.030 |
Why?
| Respiratory Mucosa | 1 | 2012 | 4 | 0.030 |
Why?
| Macrophages, Alveolar | 1 | 2012 | 2 | 0.030 |
Why?
| Spectrin | 1 | 2012 | 2 | 0.030 |
Why?
| Mitochondrial Membrane Transport Proteins | 1 | 2012 | 2 | 0.030 |
Why?
| Phosphoproteins | 1 | 2012 | 14 | 0.030 |
Why?
| HLA-DR Antigens | 2 | 2002 | 7 | 0.030 |
Why?
| Vital Capacity | 1 | 2011 | 6 | 0.020 |
Why?
| Forced Expiratory Volume | 1 | 2011 | 10 | 0.020 |
Why?
| Respiratory Function Tests | 1 | 2011 | 16 | 0.020 |
Why?
| Adenoma | 1 | 2010 | 2 | 0.020 |
Why?
| Spindle Apparatus | 1 | 2010 | 3 | 0.020 |
Why?
| 2',5'-Oligoadenylate Synthetase | 1 | 2010 | 1 | 0.020 |
Why?
| Gene Order | 1 | 2010 | 1 | 0.020 |
Why?
| Alkyl and Aryl Transferases | 1 | 2010 | 2 | 0.020 |
Why?
| Adenomatous Polyposis Coli Protein | 1 | 2010 | 5 | 0.020 |
Why?
| Mosaicism | 1 | 2010 | 9 | 0.020 |
Why?
| Karyotyping | 1 | 2010 | 11 | 0.020 |
Why?
| Adenocarcinoma | 1 | 2010 | 9 | 0.020 |
Why?
| Chromosome Disorders | 1 | 2010 | 7 | 0.020 |
Why?
| Chromosomes, Human, Pair 3 | 1 | 2010 | 2 | 0.020 |
Why?
| Quantitative Trait, Heritable | 1 | 2010 | 2 | 0.020 |
Why?
| Chromosomes, Human, Pair 14 | 1 | 2010 | 2 | 0.020 |
Why?
| Filamins | 1 | 2009 | 2 | 0.020 |
Why?
| Gene Silencing | 1 | 2010 | 13 | 0.020 |
Why?
| T-Lymphocyte Subsets | 1 | 2009 | 1 | 0.020 |
Why?
| Vitamin B 12 Deficiency | 1 | 2009 | 2 | 0.020 |
Why?
| Italy | 1 | 2009 | 3 | 0.020 |
Why?
| Age of Onset | 1 | 2009 | 28 | 0.020 |
Why?
| Melanoma | 1 | 2009 | 12 | 0.020 |
Why?
| Transfection | 1 | 2009 | 22 | 0.020 |
Why?
| Chromosomes, Human, Pair 8 | 1 | 2008 | 11 | 0.020 |
Why?
| Hong Kong | 1 | 2007 | 2 | 0.020 |
Why?
| Spinal Fractures | 1 | 2007 | 3 | 0.020 |
Why?
| Pelvic Bones | 1 | 2007 | 7 | 0.020 |
Why?
| Gene Components | 1 | 2006 | 1 | 0.020 |
Why?
| Mice, Congenic | 1 | 2006 | 2 | 0.020 |
Why?
| Crosses, Genetic | 1 | 2006 | 6 | 0.020 |
Why?
| Genome, Insect | 1 | 2005 | 1 | 0.020 |
Why?
| Oligonucleotides | 1 | 2005 | 4 | 0.020 |
Why?
| Cost-Benefit Analysis | 1 | 2005 | 25 | 0.020 |
Why?
| California | 1 | 2005 | 15 | 0.020 |
Why?
| Animals, Wild | 1 | 2004 | 1 | 0.010 |
Why?
| Sequence Homology, Nucleic Acid | 1 | 2004 | 4 | 0.010 |
Why?
| Animals, Laboratory | 1 | 2004 | 2 | 0.010 |
Why?
| Oxidoreductases Acting on CH-NH Group Donors | 1 | 2003 | 1 | 0.010 |
Why?
| Nutritional Status | 1 | 2003 | 17 | 0.010 |
Why?
| HLA-DR Serological Subtypes | 1 | 2002 | 1 | 0.010 |
Why?
| HLA-DQ beta-Chains | 1 | 2002 | 2 | 0.010 |
Why?
| HLA-DRB1 Chains | 1 | 2002 | 5 | 0.010 |
Why?
| Hungary | 1 | 2001 | 1 | 0.010 |
Why?
| Disease Susceptibility | 1 | 1998 | 11 | 0.010 |
Why?
| Immunoglobulin Heavy Chains | 1 | 1997 | 1 | 0.010 |
Why?
| Receptors, Antigen, T-Cell, alpha-beta | 1 | 1997 | 1 | 0.010 |
Why?
| Interleukin-1 | 1 | 1997 | 6 | 0.010 |
Why?
| Receptors, Interleukin-1 | 1 | 1997 | 9 | 0.010 |
Why?
|
|
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|